Flu Treatment Market Size- By Types, By Medication, By Route of Administration, By Distribution Channel, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Description

Global Flu Treatment Market Overview

According to SPER Market Research, the Global Flu Treatment Market is estimated to reach USD 1.74 billion by 2032 with a CAGR of 5.25%.

Flu, commonly known as influenza, is a typical viral infection. Chills, aches in the muscles, fever, headaches, runny nose, cough, and others are common flu symptoms. The respiratory tract is primarily impacted by flu. Influenza viruses come in four main categories: influenza A, influenza B, influenza C, and influenza D. The influenza virus types A and B that cause seasonal flu most frequently each year are A and B. The market for influenza treatments has grown due to a number of causes, including an increase in healthcare spending and R&D spending on antiviral drugs. The expansion of government programmes to fight the flu and create reliable tests will support it. The rising cost of creating tests and equipment may restrain industry expansion. The limitations on accessibility and the availability of raw materials raise the cost of the final product.

Impact of COVID-19 on the Global Flu Treatment Market

The global market for flu medications is expanding as a result of ongoing advancements in technology and partnerships between private businesses and governmental agencies for the treatment of such pandemic flu. This is due to the COVID-19 disease, which is spreading continuously throughout the world and causing a significant number of deaths worldwide. Due to the global pandemic COVID-19, which has had a severe impact on a significant section of the population, the hospital pharmacies segment is predicted to exhibit the highest CAGR during the projection period. As a result, it is likely to encourage the market for flu medications to expand.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Type, By Medication, By Route of Administration, By Distribution Channel, By End User.

Regions covered Asia-Pacific, Europe, Middle East and Africa, North America, Latin America

Companies Covered AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., GSK plc, Lilly, Merck & Co. Inc., Mylan N.V., NATCO Pharma Limited, Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd.

Global Flu Treatment Market Segmentation:

By Type: Based on the Type, Global Flu Treatment Market is segmented as; Type A, Type B, and Type C.

By Medication: Based on the Medication, Global Flu Treatment Market is segmented as; Antiviral drugs, Antihistamines, Analgesics, and Others.

By Route of Administration: Based on the Route of Administration, Global Flu Treatment Market is segmented as; Oral, Parenteral, Others

By Distribution Channel: Based on the Distribution Channel, Global Flu Treatment Market is segmented as; Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

By End User: Based on the End User, Global Flu Treatment Market is segmented as; Hospitals, Homecare, Specialty Clinics, Others

By Region: Based on region, The Global Flu Treatment Market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Due to the concentration of international players on cutting-edge technologies, the flu treatment market in North America has seen good growth over the course of the anticipated timeframe. The American healthcare authority also released COVID-19 and flu virus testing recommendations for clinicians.

Product Code: HLCA2313

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source
- 2.1.1 Secondary data
- 2.1.2 Primary data
- 2.1.3 SPER's internal database
- 2.1.4 Premium insight from KOL's
2.2 Market size estimation
- 2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1 Drivers
- 4.1.2 Restraints
- 4.1.3 Opportunities
- 4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Flu Treatment Market

5. Market variables and outlook

5.1. SWOT analysis
- 5.1.1 Strengths
- 5.1.2 Weaknesses
- 5.1.3 Opportunities
- 5.1.4 Threats
5.2. PESTEL analysis
- 5.2.1 Political landscape
- 5.2.2 Economic landscape
- 5.2.3 Social landscape
- 5.2.4 Technological landscape
- 5.2.5 Environmental landscape
- 5.2.6 Legal landscape
5.3. PORTER'S five forces analysis
- 5.3.1 Bargaining power of suppliers
- 5.3.2 Bargaining power of Buyers
- 5.3.3 Threat of Substitute
- 5.3.4 Threat of new entrant
- 5.3.5 Competitive rivalry
5.4. Heat map analysis

6. Competitive Landscape

6.1 Global Flu Treatment Manufacturing Base Distribution, Sales Area, Product Type
6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Flu Treatment Market

7. Global Flu Treatment Market, By Type, 2019-2032 (USD Million)

7.1. Type A
7.2. Type B
7.3. Type C

8. Global Flu Treatment Market, By Medication, 2019-2032 (USD Million)

8.1. Antiviral drugs
8.2. Antihistamines
8.3. Analgesics
8.4. Others

9. Global Flu Treatment Market, By Route of Administration, 2019-2032 (USD Million)

9.1. Oral
9.2. Parenteral
9.3. Others

10. Global Flu Treatment Market, By Distribution Channel, 2019-2032 (USD Million)

10.1. Hospital Pharmacy
10.2. Online Pharmacy
10.3. Retail Pharmacy

11. Global Flu Treatment Market, By End User, 2019-2032 (USD Million)

11.1. Hospitals
11.2. Homecare
11.3. Specialty Clinics
11.4. Others

12. Global Flu Treatment Market, By Region, 2019-2032 (USD Million)

12.1. Global Flu Treatment Market Size and Market Share by Region (2019-2025)
12.2. Global Flu Treatment Market Size and Market Share by Region (2026-2032)
12.3. Asia-Pacific
- 12.3.1. Australia
- 12.3.2. China
- 12.3.3. India
- 12.3.4. Japan
- 12.3.5. South Korea
- 12.3.6. Rest of Asia-Pacific
12.4. Europe
- 12.4.1. France
- 12.4.2. Germany
- 12.4.3. Italy
- 12.4.4. Spain
- 12.4.5. United Kingdom
- 12.4.6. Rest of Europe
12.5. Middle East and Africa
- 12.5.1. Kingdom of Saudi Arabia
- 12.5.2. United Arab Emirates
- 12.5.3. Rest of Middle East & Africa
12.6. North America
- 12.6.1. Canada
- 12.6.2. Mexico
- 12.6.3. United States
12.7. Latin America
- 12.7.1. Argentina
- 12.7.2. Brazil
- 12.7.3. Rest of Latin America

13. Company Profiles

13.1. AstraZeneca
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. Bayer AG
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Bristol-Myers Squibb Company
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. F. Hoffmann-La Roche Ltd.
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. GSK plc
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. Lilly
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Merck & Co. Inc.
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Mylan N.V.
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. NATCO Pharma Limited
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Novartis AG
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Pfizer Inc.
- 13.11.1. Company details
- 13.11.2. Financial outlook
- 13.11.3. Product summary
- 13.11.4. Recent developments
13.12. Sanofi
- 13.12.1. Company details
- 13.12.2. Financial outlook
- 13.12.3. Product summary
- 13.12.4. Recent developments
13.13. Sun Pharmaceutical Industries Ltd.
- 13.13.1. Company details
- 13.13.2. Financial outlook
- 13.13.3. Product summary
- 13.13.4. Recent developments